Montefiore Einstein Awarded FDA Grant for Clinical Trial on Experimental Blood Cancer Treatment

Two related blood cancers that disproportionally target older adults called acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), are notoriously difficult to treat and are associated with high relapse rates, according to medical experts at Montefiore Einstein Comprehensive Cancer Center (MECCC). Although new therapies have improved survival rates, they say treatment options remain limited, and the prognosis for the 50% of people who have these cancers, remains poor.